A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC

Sponsor
Yanqiao Zhang
Study ID
NCT03793725
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR1210 — DRUG
    Anti-PD-1 Antibody
  • Apatinib — DRUG
    Anti-angiogenic drugs

Study Details

This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With unresectable Hepatocellular Carcinoma. This study aims to evaluate the safety and efficacy of SHR-1210 combination with Apatinib as a preoperative treatment of unresectable HCC.

Key Dates

Start date
Jan 30, 2019
Status verified
Jan 2019
Primary completion
Jan 30, 2020
Completion
Jan 30, 2021

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-1210 + Apatinib
    Drug: SHR-1210 SHR-1210 was administered 200mg iv every 2 weeks Drug: Apatinib Apatinib was administered 500mg oral daily during the first 2 weeks and then 250 mg qd

Primary Outcome Measure

R0 (resection rate) [ Time Frame: 1 week after surgery ]

Central Contacts

Related Studies